Bone Biologics is pursuing a better and more effective way of dealing with back pain requiring surgery by developing bone regeneration in spinal fusion using the recombinant human protein known as NELL-1/DBX, or NB1. The company continues with human trials and reported 3Q2025 financial results that showed good cash balances that should allow testing results to bolster BBLG.
